Entasis Therapeutics Holdings Inc. operates as a clinical-stage biopharmaceutical enterprise, dedicated to the discovery, development, and market introduction of novel antibacterial solutions. Their core mission in the United States is to address severe infections stemming from pathogens that exhibit multidrug resistance. A flagship program in their pipeline is sulbactam-durlobactam (SUL-DUR), an innovative intravenous antibiotic. This promising candidate is currently undergoing Phase III clinical evaluation for its effectiveness in treating pneumonia and bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii. The company's developmental efforts extend to several other therapeutic agents. Zoliflodacin, a distinct orally administered molecule, is also progressing through Phase III clinical trials, aimed at uncomplicated gonorrhea. Furthermore, ETX0282CPDP, an oral drug, is being assessed in Phase I studies for its potential in treating urinary tract infections. From their NBP platform, ETX0462 is another drug candidate, presently in the pre-clinical stage, targeting a range of multidrug-resistant gram-negative infections. Entasis maintains key partnerships to advance its portfolio. A licensing and collaboration agreement is in place with Zai Lab (Shanghai) Co., Ltd. for the continued development of durlobactam and SUL-DUR. Additionally, they have a collaborative arrangement with the Global Antibiotic Research and Development Partnership for the development and subsequent commercialization of Zoliflodacin. Established in 2015, Entasis Therapeutics Holdings Inc. maintains its corporate headquarters in Waltham, Massachusetts, and functions as a subsidiary of Innoviva, Inc.